Track topics on Twitter Track topics that are important to you
Cardiovascular medicine is struggling with the new proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor drugs for lowering low-density lipoprotein cholesterol (LDL), not primarily because of efficacy concerns or safety issues, but because the price of these new agents exceeds $14 000 a year. While clinicians are seeking to understand how best to exploit the potential for enhanced protection these drugs may provide to patients at risk of atherosclerotic complications (such as myocardial infarction and stroke), payers are focused on constraining the use of these medications, recognizing that the pool of candidates for PCSK9 inhibitor drugs is enormous.NEXT ARTICLE
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...